Wedbush Analysts Increase Earnings Estimates for Obseva SA (OBSV)

Obseva SA (NASDAQ:OBSV) – Wedbush boosted their FY2018 earnings per share (EPS) estimates for Obseva in a research note issued on Tuesday, November 13th. Wedbush analyst L. Moussatos now forecasts that the company will post earnings of ($1.93) per share for the year, up from their prior estimate of ($2.00). Wedbush currently has a “Buy” rating and a $34.00 target price on the stock. Wedbush also issued estimates for Obseva’s Q4 2018 earnings at ($0.49) EPS, Q1 2019 earnings at ($0.47) EPS, Q2 2019 earnings at ($0.45) EPS, Q3 2019 earnings at ($0.45) EPS, Q4 2019 earnings at ($0.45) EPS, FY2019 earnings at ($1.82) EPS, FY2020 earnings at ($2.21) EPS, FY2021 earnings at ($2.84) EPS and FY2022 earnings at ($1.97) EPS.

Obseva (NASDAQ:OBSV) last posted its quarterly earnings results on Thursday, November 8th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.04.

A number of other brokerages also recently commented on OBSV. Zacks Investment Research raised Obseva from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research report on Thursday, October 18th. HC Wainwright set a $44.00 price target on Obseva and gave the company a “buy” rating in a report on Wednesday, August 8th. Leerink Swann started coverage on Obseva in a report on Wednesday, August 15th. They issued an “outperform” rating and a $25.00 price objective for the company. TheStreet raised Obseva from a “d+” rating to a “c-” rating in a report on Thursday, October 11th. Finally, JPMorgan Chase & Co. began coverage on Obseva in a research note on Thursday, September 13th. They set an “overweight” rating and a $29.00 price target for the company. Eight analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average price target of $29.43.

Shares of OBSV opened at $12.91 on Friday. The stock has a market capitalization of $514.11 million, a P/E ratio of -5.74 and a beta of 1.75. Obseva has a 12-month low of $9.05 and a 12-month high of $20.35.

Institutional investors and hedge funds have recently bought and sold shares of the stock. US Bancorp DE acquired a new stake in shares of Obseva during the second quarter valued at $197,000. United Services Automobile Association acquired a new stake in shares of Obseva during the third quarter valued at $206,000. Tiverton Asset Management LLC acquired a new stake in shares of Obseva during the second quarter valued at $224,000. Dimensional Fund Advisors LP acquired a new stake in shares of Obseva during the third quarter valued at $340,000. Finally, Jane Street Group LLC acquired a new stake in shares of Obseva during the second quarter valued at $349,000. 68.34% of the stock is currently owned by institutional investors and hedge funds.

About Obseva

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Featured Article: Compound Interest

Earnings History and Estimates for Obseva (NASDAQ:OBSV)

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply